Equities researchers at CIBC initiated coverage on shares of Recro Pharma (NASDAQ:REPH) in a note issued to investors on Wednesday. The firm set an “outperform” rating and a $19.00 price target on the specialty pharmaceutical company’s stock. CIBC’s price objective suggests a potential upside of 131.43% from the stock’s current price.
REPH has been the topic of several other research reports. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a report on Wednesday, November 15th. Piper Jaffray Companies restated a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a report on Friday, October 27th. UBS Group initiated coverage on Recro Pharma in a report on Tuesday. They set an “outperform” rating on the stock. Finally, Oppenheimer initiated coverage on Recro Pharma in a report on Tuesday. They set an “outperform” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $13.75.
Recro Pharma (NASDAQ REPH) traded up $0.12 during trading on Wednesday, reaching $8.21. The company’s stock had a trading volume of 47,700 shares, compared to its average volume of 110,329. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $154.74, a P/E ratio of -3.75 and a beta of -0.60. Recro Pharma has a one year low of $5.81 and a one year high of $10.59.
Institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC acquired a new position in Recro Pharma in the second quarter valued at $162,000. California State Teachers Retirement System acquired a new position in Recro Pharma in the second quarter valued at $169,000. JPMorgan Chase & Co. boosted its holdings in Recro Pharma by 183.4% in the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after acquiring an additional 14,098 shares during the last quarter. Strs Ohio boosted its holdings in Recro Pharma by 455.0% in the fourth quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock valued at $205,000 after acquiring an additional 18,200 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in Recro Pharma in the second quarter valued at $215,000. Hedge funds and other institutional investors own 61.88% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/14/recro-pharma-reph-earns-outperform-rating-from-analysts-at-cibc.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.